A few things from the Acutaas Annual Report for FY2025:
The word Acutaas is inspired by the Latin word acutus — meaning sharp, keen, or perceptive
The count of commercialized products is now 610+ (this was 570+ last year)
Company’s advanced capabilities across multiple synthesis stages ensure a steady pipeline; focused on new technology platforms such as Flow reactors, DCS, etc.
The company completed the majority of its capital expenditure at its Ankleshwar facility and secured a long-term supply agreement with a subsidiary of an innovator pharmaceutical company for four new pharmaceutical intermediates targeting a single API under the CDMO model. Ankleshwar facility is fully automated, incorporating a Distributed Control System (DCS) for centralized monitoring and control of operations, along with a Powder Transfer System (PTS) that enables enclosed, contact-free material handling. The plant features three dedicated production blocks equipped with over 80 reactors and approximately 35 dryers. It is GMP-certified under ICH Q7 guidelines for the manufacture and dispatch of pharmaceutical intermediates. The new plant is among the one of first automated facilities for advanced intermediates in India.
The Sachin unit houses 13 independent product lines, supported by 40 reactors and 17 dryers. Company’s Board has approved capex for a new pilot plant facility at Sachin. The pilot plant will help expedite scaling up of new products as well as manufacturing of High Potent chemicals and the new products under CRAMS model.
The Jhagadia plant is equipped with 31 stainless steel and 14 glass-lined reactors. The facility is spread across a sizable land parcel, of which 15,830 square meters was unutilized. We are now leveraging this space to establish a new plant for Battery Chemicals. Civil works for electrolyte additives plant is in process, and commissioning is on track for the second half of FY2026
Under the Advanced Pharma Intermediates vertical, the company offers capabilities to manufacture up to N–1 stages of intermediates across multiple routes of synthesis (ROS). A significant differentiator lies in our backward integration strategy — over 90 % of our pharmaceutical intermediates are integrated with basic chemicals.
In Specialty Chemicals, Acutaas is the only manufacturer of semiconductor-grade photoresist chemicals in India. In Battery Chemicals, a healthy innovation pipeline with ~10 products under development, targeted toward next-generation lithium-ion and alternative battery technologies. Key products in this segment include Vinylene Carbonate and Fluoroethylene Carbonate, among others. We have firm orders on hand for the electrolytes business.
Our goal of achieving Rs.1,000 Crore in CDMO revenue by FY2028 is well within sight
We have significantly reduced our dependence on Chinese imports, bringing China’s share of raw material imports down from more than 70 % to 21 % by 2025.
Our operations are supported by a robust Distributed Control System (DCS)* that ensures precision and consistency across batch processes and utilities. We have also adopted Powder Transfer Systems to improve material handling and containment, particularly for high-potency APIs. With advanced fully automated drying technologies, our processes are faster, cleaner, and more reliable.
We are working on Photochemistry to unlock cleaner reaction pathways and novel compound synthesis. This is currently in R&D stage (Comment: Again, we see the continuous quest to move up the value chain and adopt newer, niche, emerging, high value-added technologies by the company).
Working on vertical gravity flow systems for safer, more energy-efficient batch processing.
Did over 100 customer and regulatory inspections in FY2025.
During the year, the company received process patents for its one invention in the pharma intermediates business. Company now boasts a robust portfolio of 10 process patents. We have filed applications for seven more process patents (in respect of intermediates used in the manufacture of generic API across therapeutic segments).
Board has approved to inject Rs.200 crores for establishment of manufacturing facility in South Korea through a joint venture company. (It is interesting to see that though the Baba Fine Chem acquisition was made to get a foot into the semiconductor space, the South Korea foray is happening through a 100 % subsidiary, sidestepping BFC altogether. This will ensure benefits of the semiconductor foray are not diluted for the Acutaas shareholders, since company’s stake in BFC only 55 %). Smart strategy by the company.
Very good set of numbers. At this point of time company’s major portion of revenue comes from pharma. But, I am more interested in Specialty Chemicals segment which contributes 14% approx to the revenue.
Acutaas claims they are the only biggest manufacturer of electrolyte additives outside china. Therefore are positioned to take advantage of Battery Energy Storage System (BESS) opportunity that are coming in Energy sector.
Plus they also make semiconductor grade photoresist chemicals in India. As there are huge multiple semiconductor plants made in Dholera, Gujarat by reputed player like Tata, ReNew, Kaynes etc. Plus Torrent power has already made a huge power plant to serve electricity. This also present future opportunity to Acutaas.
What the article above is missing is their semiconductor and EV chemical business, which is kicking off next year. They already have a client locked in, and trials are going to start by the end of this year, if I remember correctly. If all three businesses scale well, the premiums it’s getting are justified. I agree with the risks associated with it. We need to monitor their execution closely. Note: I’ve been tracking this company for the last three years. Invested and biased.
